Norges Bank
CHRS icon

Norges Bank’s Coherus Oncology CHRS Stock Holding History

Norges Bank’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-491,500
Closed -$850K – 1859
2024
Q2 		$850K Buy
+491,500
New +$989K ﹤0.01% 1830
2017
Q2 		– Sell
-40,000
Closed -$846K – 2132
2017
Q1 		$846K Buy
+40,000
New +$984K ﹤0.01% 2085
2015
Q1 		– Sell
-20,000
Closed -$326K – 2290
2014
Q4 		$326K Buy
+20,000
New +$282K ﹤0.01% 2280

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank's CHRS Position: Q3 2024 in Review

Norges Bank sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 491,500 shares — an estimated $850K sold.

Norges Bank first reported a position in CHRS in Q4 2014 and held it in 3 quarters. The position peaked at $850K in Q2 2024. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

  • Norges Bank reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
  • Norges Bank sold 491,500 Coherus Oncology shares in Q3 2024, an estimated $850K.
  • Norges Bank first reported a position in Coherus Oncology in Q4 2014 and held it in 3 quarters.
  • Norges Bank's Coherus Oncology position peaked at $850K in Q2 2024.
  • 128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on Norges Bank's 13F filing for Q3 2024, filed 13 Nov 2024.